Johannes Weller

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors

Émilie Le Rhun, Patrick Devos, Johannes Weller et al. · Neuro-Oncology · 2020 · 120 citations · Full text

Medicine, Oncology, Radiology +17

Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial

Götz Thomalla, Jens Fiehler, Fabien Subtil et al. · The Lancet Neurology · 2024 · 65 citations · Full text

Medicine, Neurological Surgery, Surgery +17

Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival

Matthias Schneider, Anna‐Laura Potthoff, Elisa Scharnböck et al. · Journal of Neuro-Oncology · 2020 · 57 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Johannes Weller, Theophilos Tzaridis, Frederic Mack et al. · The Lancet Oncology · 2019 · 46 citations

Medicine, Neurology, Oncology +15